ABOS — Acumen Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $122.96m
- $9.48m
- 14
- 37
- 57
- 27
Annual income statement for Acumen Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.44 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 9.35 | 19.6 | 45.2 | 61.1 | 114 |
| Operating Profit | -7.91 | -19.6 | -45.2 | -61.1 | -114 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.33 | -101 | -42.9 | -52.4 | -102 |
| Net Income After Taxes | -7.33 | -101 | -42.9 | -52.4 | -102 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.33 | -101 | -42.9 | -52.4 | -102 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.33 | -101 | -42.9 | -52.4 | -102 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.19 | -5.02 | -1.06 | -1.08 | -1.71 |
| Dividends per Share |